P. De Simone, F. Nevens, L. De Carlis, H. J. Metselaar, S. Beckebaum, F. Saliba, S. Jonas, D. Sudan, J. Fung, L. Fischer, C. Duvoux, K. D. Chavin, B. Koneru, M. A. Huang, W. C. Chapman, D. Foltys, S. Witte, H. Jiang, J. M. Hexham, G. Junge and for the H2304 Study Group Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled Trial American Journal of Transplantation 12
Article first published online: 6 AUG 2012 | DOI: 10.1111/j.1600-6143.2012.04212.x
This prospective, randomized, multicenter, open-label study in de novo liver transplant patients shows that initiation of everolimus at day 30 posttransplant facilitates tacrolimus minimization but not elimination, and results in comparable efficacy and superior renal function but increased adverse events compared to a standard tacrolimus exposure regimen.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field